Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1
Chemoresistance is a major obstacle to effective breast cancer chemotherapy. However, the underlying molecular mechanisms remain unclear. The long noncoding RNA H19 (H19) is involved in various stages of tumorigenesis, however, its role in doxorubicin resistance remains unknown. The goal of this stu...
Main Authors: | Yu Wang, Peihong Zhou, Ping Li, Fengxia Yang, Xue-qiang Gao |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | Bioengineered |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21655979.2020.1761512 |
Similar Items
-
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
by: Hye Jeong Park, et al.
Published: (2018-05-01) -
Avoiding the Interference of Doxorubicin with MTT Measurements on the MCF-7 Breast Cancer Cell Line
by: Carla Luis, et al.
Published: (2019-04-01) -
Doxorubicin loaded magnetism nanoparticles based on cyclodextrin dendritic-graphene oxide inhibited MCF-7 cell proliferation
by: Mihanfar Ainaz, et al.
Published: (2021-04-01) -
Discovery of Novel Doxorubicin Metabolites in MCF7 Doxorubicin-Resistant Cells
by: Xu Wang, et al.
Published: (2019-12-01) -
Magnetic nanoparticles sensitize MCF-7 breast cancer cells to doxorubicin-induced apoptosis
by: Aljarrah Khaled, et al.
Published: (2012-04-01)